DIAL

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

Screened window

Feb 6, 2016 → Oct 26, 2026

Cited window

Jun 4, 2023 → Oct 25, 2026

Retrieved

Oct 28, 2026

Title

A Phase II-III Randomized Trial Evaluating Maintenance Pembrolizumab (± Pemetrexed) Until Progression Versus Observation (± Pemetrexed) After 6 Months of Platinum-based Doublet Chemotherapy Plus Pembrolizumab Induction Treatment in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)

Registry

NCT05255302

Study IDs

IFCT-2103 · 2021-006044-27

Sponsor

Intergroupe Francophone de Cancerologie Thoracique

Design

Phase 2/Phase 3 · Interventional, randomized, parallel

Status

Recruiting

Enrollment

1,360 estimated

Start

2022-05-02 actual

Primary completion

2025-05 estimated

Primary endpoint

Phase II: 18-month overall survival (OS)

Interventions

4 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Discussion that does not name the trial may be missing from this edition.
• –1 matching source (1 podcast) could not be read and is not included.
• –For 1 recording, a transcript separated by speaker was not available, so quotes come from the original automatic transcript and may lack speaker labels.
• –Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
• –32 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
• –Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
• –The report represents only the sources reviewed for this edition. Reposts, organizational or account-level posts, and reports of talks do not establish a count of independent HCP endorsements or a consensus.
• –Searches emphasized trial identifiers and names; unnamed references, short acronyms and transcription variants may be missing, including discussion of the same clinical question without the DIAL name.
• –One podcast was unavailable, additional checking of a video transcript was unsuccessful, and four potentially relevant social-media passages were not fully assessed. Additional views or qualifications may therefore be absent.
• –No DIAL results publication was available among the reviewed sources, and no separate protocol was listed in the registry material. Numerical phase II findings are presented as authors' reports rather than conclusions from a reviewed trial results publication.
• –The cited safety summaries use different adverse-event categories and values. Their denominators, grades and statistical uncertainty are not available in the statements cited, so the figures should not be pooled or treated as interchangeable.
• –Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
• –Comments span posts dated 2023–2026 and different events. Post dates are not session dates and do not demonstrate changes in an author's position.

How reports are built and checked: Methods.

Last checked for new commentary Oct 28, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update. No corrections.

Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.

Help me decide whether to buy the Erudio report "DIAL" (NCT05255302), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.

1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "dial-05255302". If you cannot make requests, read https://www.erudio.com/reports/dial-nct05255302.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email and the product: the current edition, or 3, 6 or 12 months of weekly updates. Call create_order with report "NCT05255302", that product and email, then show me the quote and the checkout_url to pay by card. If you have a payment client for HTTP 402 payments and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id erudio-nct05255302 and sections ["all"], and summarize the findings for me with their sources. The full report is large (about 500 KB): save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.

When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.

curl https://www.erudio.com/reports/dial-nct05255302.json
curl https://www.erudio.com/reports/dial-nct05255302.md

# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "dial-05255302" })